Enbrel Access is Plummeting

Discussion in 'Amgen' started by anonymous, Jun 4, 2017 at 2:07 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Asian 40 year old virgin will fail. He will make some fancy slides on it but this product is doomed. Amgen should just face the facts and move in. Milk it as long as possible and move to the next big thing
     

  2. anonymous

    anonymous Guest

    Too bad all the recent contracts are creating a price war on steroids through discounts. By the time Amjevita is launched a lot of value will be dissolved. A few biosims will get into the market and we will be looking at net prices well below 10k per patient/yr. This many competitors splitting market share is recipe for a disaster. This is why Allergan pulled out of biosims, while we go full Amgen.
     
  3. anonymous

    anonymous Guest

    Allergan is still partnered for herceptin biosim.
     
  4. anonymous

    anonymous Guest

    Amgen Compliance - really? A bunch of fucking r*****s.
    Like the island of misfit toys. Those assholes have no clue, basically shills for Amgen HR.
     
  5. anonymous

    anonymous Guest

    They're getting paid overtime to monitor CP at home, flagging every new post and hopingfor the best.
     
  6. anonymous

    anonymous Guest

    It's had it's time- still good product
     
  7. anonymous

    anonymous Guest

    A decrease in share of a third is a lot in one year. It's embarrassing.
     
  8. anonymous

    anonymous Guest

    It's getting worse. Even if the coverage ever changed for us. Most docs won't consider is when humira is now standard of care for most autoimmune diseases.
     
  9. anonymous

    anonymous Guest

    Docs are being pushed to try Remicade biosimilars first before self-injected products. This is a mess.
     
  10. anonymous

    anonymous Guest

    The Enbrel man JC will fix all of this. Nothing an inexperienced MIT grad can't handle.
     
  11. anonymous

    anonymous Guest

    Jc and his ilk are the reason access is getting worse. The people before him who raised enbrel price quarterly. The people he hired to fix it Can't.
     
  12. anonymous

    anonymous Guest

    Brand team should demand changes before we lose more share.
     
  13. anonymous

    anonymous Guest

    OP nice post. True
     
  14. anonymous

    anonymous Guest

    Even if we get reimbursement contracts back, prescribers have already made other products their workhorse go to product for specific patients. What's gone is gone for good. It's just a matter of time until someone realizes we don't need 4 reps at once.

    It's become beyond embarrassing. Old marketing pieces waste prescribers' time. Rejections and prior authorizations are a waste of prescribers' time. Give us something to work with.

    We're better off sitting at home and praying for more patients to be diagnosed and treated rather than wasting their time showing them the same marketing piece as 10 years ago.
     
  15. anonymous

    anonymous Guest

    Give Phil Mickelson a sales territory. It seems he can't really play golf very well anymore. Perhaps he could turn declining SOM round vs. Xeljanz/Humira....
    Maybe he can make it to Presidents Council?

    Perhaps he would enjoy a warehouse dash?
     
  16. anonymous

    anonymous Guest

    Phil would really take a pill

    I asked him